Barbara Noris Chiorda

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8337658/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	How to implement the requirements of a quality assurance system for prostate cancer. World Journal of Urology, 2021, 39, 41-47.	2.2	1
2	Acute patient-reported intestinal toxicity in whole pelvis IMRT for prostate cancer: Bowel dose-volume effect quantification in a multicentric cohort study. Radiotherapy and Oncology, 2021, 158, 74-82.	0.6	5
3	Predictors of Patient-Reported Incontinence at Adjuvant/Salvage Radiotherapy after Prostatectomy: Impact of Time between Surgery and Radiotherapy. Cancers, 2021, 13, 3243.	3.7	2
4	Predictors of 2-Year Incidence of Patient-Reported Urinary Incontinence After Post-prostatectomy Radiotherapy: Evidence of Dose and Fractionation Effects. Frontiers in Oncology, 2020, 10, 1207.	2.8	7
5	Assessing the Role and Optimal Duration of Hormonal Treatment in Association with Salvage Radiation Therapy After Radical Prostatectomy: Results from a Multi-Institutional Study. European Urology, 2019, 76, 443-449.	1.9	14
6	More Extensive Lymph Node Dissection at Radical Prostatectomy is Associated with Improved Outcomes with Salvage Radiotherapy for Rising Prostate-specific Antigen After Surgery: A Long-term, Multi-institutional Analysis. European Urology, 2018, 74, 134-137.	1.9	13
7	Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series. European Urology, 2018, 73, 512-518.	1.9	36
8	Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy. European Urology, 2018, 73, 436-444.	1.9	60
9	Active surveillance in prostate cancer patients: Modeling upgrading and upsizing at 1 year rebiopsy Journal of Clinical Oncology, 2018, 36, 90-90.	1.6	0
10	Patient-reported intestinal toxicity from whole pelvis intensity-modulated radiotherapy: First quantification of bowel dose–volume effects. Radiotherapy and Oncology, 2017, 124, 296-301.	0.6	26
11	PD72-10 ASSESSING THE RISK OF EARLY AND LATE TOXICITY OFÂPOST-PROSTATECTOMY RADIATION THERAPY: AÂLONG-TERM MULTI-INSTITUTIONAL ANALYSIS. Journal of Urology, 2017, 197, .	0.4	0
12	PD51-02 IDENTIFYING THE OPTIMAL CANDIDATE FOR EARLY SALVAGE RADIATION THERAPY AFTER RADICAL PROSTATECTOMY FOR PROSTATE CANCER: A LONG-TERM MULTI-INSTITUTIONAL ANALYSIS. Journal of Urology, 2017, 197, .	0.4	0
13	PD72-03 TIMING OF SALVAGE RADIATION THERAPY AND USE OF CONCOMITANT HORMONAL THERAPY FOR PATIENTS WITH PSA RISING AFTER RADICAL PROSTATECTOMY: AÂLONG-TERM SURVIVAL ANALYSIS. Journal of Urology, 2017, 197, .	0.4	1
14	Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3NO Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series. European Urology, 2017, 71, 886-893.	1.9	77
15	Moderate Hypofractionation with Simultaneous Integrated Boost in Prostate Cancer: Long-term Results of a Phase l–ll Study. Clinical Oncology, 2016, 28, 490-500.	1.4	21
16	MP14-10 DETRIMENTAL ROLE OF PRE-PROSTATECTOMY NEOADJUVANT ANDROGEN DEPRIVATION IN NODE-NEGATIVE PATIENTS TREATED WITH ADJUVANT RT. Journal of Urology, 2016, 195, .	0.4	0
17	MP14-07 PATTERNS AND PREDICTORS OF CLINICAL RECURRENCE FOLLOWING EARLY SALVAGE RADIATION THERAPY IN PATIENTS WITH PSA RISE AFTER RADICAL PROSTATECTOMY: A LONG TERM MULTI-INSTITUTIONAL ANALYSIS. Journal of Urology, 2016, 195, .	0.4	0
18	MP14-08 LONG-TERM IMPACT OF ADJUVANT VERSUS EARLY SALVAGE RADIATION THERAPY ON CLINICAL RECURRENCE IN PT3NO PROSTATE CANCER PATIENTS TREATED WITH RADICAL PROSTATECTOMY: RESULTS OF A MULTI-INSTITUTIONAL ANALYSIS. Journal of Urology, 2016, 195, .	0.4	0

#	Article	IF	CITATIONS
19	MP14-11 WHEN IS THE OPTIMAL TIMING FOR SALVAGE RADIATION THERAPY IN PATIENTS WITH INCREASING PSA AFTER RADICAL PROSTATECTOMY? A PATIENT RISK STRATIFICATION MODEL BASED ON PROSTATE CANCER AGGRESSIVENESS. Journal of Urology, 2016, 195, .	0.4	0
20	MP84-13 A NEW APPROACH FOR AN IMPROVED PSA DOUBLING TIME COMPUTATION FOR SELECTING PATIENTS CANDIDATE TO TIMELY SALVAGE RADIOTHERAPY FOR A BIOCHEMICAL RECURRENCE AFTER PROSTATECTOMY. Journal of Urology, 2016, 195, .	0.4	0
21	Dose–volume effects for pelvic bone marrow in predicting hematological toxicity in prostate cancer radiotherapy with pelvic node irradiation. Radiotherapy and Oncology, 2016, 118, 79-84.	0.6	68
22	Hematologic Toxicity in Patients Treated With Postprostatectomy Whole-Pelvis Irradiation With Different Intensity Modulated Radiation Therapy Techniques Is Not Negligible and Is Prolonged: Preliminary Results of a Longitudinal, Observational Study. International Journal of Radiation Oncology Biology Physics, 2016, 95, 690-695.	0.8	26
23	Higher-than-expected Severe (Grade 3–4) Late Urinary Toxicity After Postprostatectomy Hypofractionated Radiotherapy: A Single-institution Analysis of 1176 Patients. European Urology, 2014, 66, 1024-1030.	1.9	94